TransMedics Group (NASDAQ:TMDX) Director Thomas Gunderson Sells 9,624 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) Director Thomas Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TransMedics Group Stock Performance

TMDX stock traded down $2.60 during trading hours on Wednesday, reaching $73.22. The stock had a trading volume of 862,461 shares, compared to its average volume of 1,090,523. The stock has a 50-day simple moving average of $85.20 and a 200 day simple moving average of $114.02. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The stock has a market capitalization of $2.53 billion, a PE ratio of 16.64 and a beta of 1.91. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Analysts predict that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

Institutional Trading of TransMedics Group

Several institutional investors have recently added to or reduced their stakes in TMDX. Kensington Investment Counsel LLC bought a new position in TransMedics Group during the third quarter worth about $1,926,000. Fieldview Capital Management LLC bought a new stake in TransMedics Group in the 3rd quarter valued at about $1,716,000. Citigroup Inc. grew its position in shares of TransMedics Group by 29.3% during the 3rd quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after purchasing an additional 17,414 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of TransMedics Group by 303.8% during the third quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock worth $16,913,000 after purchasing an additional 113,408 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of TransMedics Group by 78.9% during the third quarter. Envestnet Asset Management Inc. now owns 47,048 shares of the company’s stock worth $5,279,000 after purchasing an additional 20,750 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TMDX. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. TD Cowen cut their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Needham & Company LLC reduced their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus dropped their price objective on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating on the stock in a research report on Tuesday, May 26th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Hold” and a consensus target price of $134.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.